Table 1 Patient characteristics.
Patients with follicular lymphoma | All (n = 45) |
|---|---|
Age at alloSCT, median (range), years | 57 (34–71) |
Female gender, n (%) | 18 (40) |
Pretreatments before alloSCT, median (range) | 4 (2–8) |
Remission status at alloSCT, n (%) | |
CR | 9 (20) |
PR | 27 (60) |
SD | 1 (2) |
PD/primary refractory | 6 (13) |
Unknown | 2 (4) |
Good performance status at alloSCT (Karnofsky 90–100%), n (%) | 30/42 (71) |
Matched related donor n (%) | 12 (27) |
Conditioning, n (%) | |
TBI based | 13 (29) |
Alkylator based | 32 (71) |
Alemtuzumab | 5 (11) |
ATG | 22 (49) |
Reduced intensity conditioninga (RIC), n (%) | 31 (69) |
Idelalisib administration, n (%) | |
Monotherapy | |
Anti-CD20 antibody combination | 11 (24) |
Chemotherapy combination | 2 (4) |
AutoSCT prior to alloSCT, n (%) | 22 (49) |
Median follow-up of survivors, months after alloSCT (range) | 12 (2–35) |
